Notes: Sergliflozin A is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; Ki = 2.39 nM for the human transporter) and an active metabolite of sergliflozin etabonate.{69948} It is formed from sergliflozin etabonate by esterases and selectively inhibits SGLT2 over SGLT1 (Ki = 708 nM for the human transporter). Co-infusion of sergliflozin A and glucose reduces maximal renal glucose reabsorption rates in rats.